Sanofi and Alloy Therapeutics have partnered to develop a new antisense oligonucleotide (ASO) therapy for a CNS condition. Sanofi will pay Alloy up to $27.5m upfront and $400m+ in milestone payments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing